These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 19031567

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. FDA notifications. Raltegravir indication extended for treatment-naive patients.
    AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV.
    Ter Arkh; 2010 Aug; 82(11):27-32. PubMed ID: 21381345
    [Abstract] [Full Text] [Related]

  • 27. Raltegravir. In HIV-infected in children at least 2 years of age. Only after prior treatment failure.
    Prescrire Int; 2014 Sep; 23(152):206. PubMed ID: 25325117
    [Abstract] [Full Text] [Related]

  • 28. Study explains Isentress' excellent resistance profile.
    Proj Inf Perspect; 2008 Dec; (47):3. PubMed ID: 19226674
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this year.
    Albrecht H.
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20626067
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Treatment of HIV infection with raltegravir.
    Chirch LM, Morrison S, Steigbigel RT.
    Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
    [Abstract] [Full Text] [Related]

  • 34. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
    AIDS Rev; 2009 May; 11(1):17-29. PubMed ID: 19290031
    [Abstract] [Full Text] [Related]

  • 35. Trial will evaluate a once-daily dose of raltegravir.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
    [No Abstract] [Full Text] [Related]

  • 36. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG, Brinkman K.
    Ned Tijdschr Geneeskd; 2009 Jan 31; 153(5):166-7. PubMed ID: 19256240
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [A clinical study with an HIV integrase inhibitor].
    Winckler T.
    Pharm Unserer Zeit; 2007 Jan 31; 36(4):251-2. PubMed ID: 17623312
    [No Abstract] [Full Text] [Related]

  • 40. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.
    Rowley M.
    Prog Med Chem; 2008 Jan 31; 46():1-28. PubMed ID: 18381123
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.